Home/Pipeline/HGF protein

HGF protein

Amyotrophic Lateral Sclerosis (ALS)

Phase 2Phase I completed in Japan (2015)

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 2

Status

Phase I completed in Japan (2015)

Company

Kringle Pharma, Kringle Pharma, Kringle Pharma

About Kringle Pharma

Late-stage biotech developing HGF protein therapies for intractable neurological and regenerative diseases, with lead program in acute spinal cord injury.

View full company profile

About Kringle Pharma

Late-stage biotech developing HGF protein therapies for intractable neurological and regenerative diseases, with lead program in acute spinal cord injury.

View full company profile

About Kringle Pharma

Late-stage biotech developing HGF protein therapies for intractable neurological and regenerative diseases, with lead program in acute spinal cord injury.

View full company profile

Therapeutic Areas

Neuroscience Regenerative Medicine Rare Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active